Core Insights - Actuate Therapeutics, Inc. announced that topline clinical data from its Phase 2 study of elraglusib in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma has been selected for oral presentation at the 2025 ASCO Annual Meeting [1][2] Company Overview - Actuate Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1][3] - The lead investigational drug, elraglusib, targets molecular pathways involved in tumor growth and resistance to conventional cancer drugs, potentially mediating anti-tumor immunity [3] Presentation Details - The oral presentation will include preliminary results from the randomized Phase 2 study comparing elraglusib in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel alone in previously untreated patients with metastatic pancreatic ductal adenocarcinoma [2] - The session is scheduled for May 31, 2025, from 3:00 PM to 6:00 PM CDT, under the title "Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary" [3]
Actuate to Present Elraglusib Phase 2 Topline Data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting